Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 503 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-fasting Clear all

Conditions: ACL, Opioid Use, Cryotherapy Effect, Vibration; Exposure, Pain, Postoperative
Interventions: VibraCool mechanical stimulation and neuromodulatory therapeutic device, Cryocompression (Game Ready, Bregs) device, Standard ice packs; Device
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: C-Met Exon 14 Mutation
Interventions: Glumetinib; Drug
Lead sponsor: Haihe Biopharma Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Healthy
Interventions: Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Mass Casualty
Interventions: SonoSite Ultrasound; Procedure
Lead sponsor: Ascension Health; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Grand Blanc, Michigan

Conditions: Healthy
Interventions: Fexofenadine 180 mg tablets, ALLEGRA® 180 mg tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Type 2 Diabetes, Overweight, Obesity
Interventions: Liraglutide, Metformin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Intermittent fasting; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ischemic Stroke
Interventions: Enhanced Stroke Education, Usual Stroke Education; Behavioral
Lead sponsor: Washington Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Anterior Knee Pain Syndrome, Patellofemoral Pain Syndrome
Interventions: Dry Needling, Soft Tissue Mobilization, Placebo Control, Hip and core strengthening exercises; Other
Lead sponsor: Mitchell Selhorst; Other
Eligibility: 13 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: Prolonged Nightly Fasting, Exercise; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Impairment, Healthy Participants
Interventions: Linzagolix; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Orlando, Florida • Saint Paul, Minnesota

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: University of North Carolina; Other
Eligibility: 20 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer Prevention, Mammographic Density
Interventions: Ultrasound-guided core needle biopsy, Denosumab, Blood draw, Calcium, Vitamin D; Procedure · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 35 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: Azithromycin, Zithromax®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Seborrheic Dermatitis
Interventions: Biopsy; Procedure
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Invasive Cardiac Catheterization (ICA), Coronary Computed Tomographic Angiogram (CCTA), Dynamic Cardiac Positron Emission Tomography (dPET); Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia • Roslyn, New York

Conditions: Raynaud, Scleroderma
Interventions: Fasudil; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Diseases
Interventions: Coronary angiogram, Right heart catheterization; Procedure
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions: Patient-led Insulin (intervention group), Provider-led Insulin (standard care); Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 12
States / cities: Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more

Conditions: Alzheimer's Disease
Interventions: J147, Placebo; Drug
Lead sponsor: Abrexa Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

VibraCool Device to Reduce Pain and Opioid Use After Anterior Cruciate Ligament Reconstruction (ACLR)

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions

A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions

The Use of the FAST (Focused Abdominal Scan for Trauma) Scan by Paramedics in Mass Casualty Incidents

Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Intermittent Fasting in Multiple Sclerosis

REcurrent Stroke Prevention Through Personalized Education by Clinical Trainers (RESPPECT Trial)

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Manual Therapy to Treat Gluteus Medius Trigger Points

Feasibility of Fasting & Exercise in Pts With HR+ MBC

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes

RANKL Inhibition and Breast Tissue Biomarkers

A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions

Magnetocardiography (MCG) in Asymptomatic Individuals - Pilot Trial

Neurobiology of the Scalp in Seborrheic Dermatitis

Quantification of Myocardial Blood Flow Using Dynamic PET/CTA Fused Imagery

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

Fasting Versus Non-fasting on Outcomes and Satisfaction Prior to Cardiac Catheterization

Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147